carnitine has been researched along with Cardiac Diseases in 47 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Perfluorooctanoic acid (PFOA), a wide spread environmental pollutant, was associated with developmental cardiotoxicity in chicken embryo, while the underlying molecular mechanism had not been fully elucidated." | 7.88 | The roles of bone morphogenetic protein 2 in perfluorooctanoic acid induced developmental cardiotoxicity and l-carnitine mediated protection. ( Cui, L; Han, Y; Jiang, Q; Lv, N; Wang, C; Zhao, M; Zhong, W, 2018) |
| "In total, 32 patients with beta-thalassemia major were recruited; 16 age- and sex-matched children constituted the control group." | 5.35 | Pulmonary hypertension in beta-thalassemia major and the role of L-carnitine therapy. ( El Accaoui, R; El-Beshlawy, A; El-Saidi, S; Makhlouf, A; Mansi, Y; Taher, A; Youssry, I, 2008) |
| "Acute and chronic L-carnitine application exerts protective effects in a number of cardiac diseases." | 5.09 | Prolonged oral L-carnitine substitution increases bicycle ergometer performance in patients with severe, ischemically induced cardiac insufficiency. ( Löster, H; Miehe, K; Pankau, H; Punzel, M; Schauer, J; Stiller, O, 1999) |
| " Because of its trophic action on the myocardial tissue, the use of L-carnitine has been evaluated during IL-2 therapy in advanced cancer patients with clinically important cardiac diseases." | 5.07 | Prevention by L-carnitine of interleukin-2 related cardiac toxicity during cancer immunotherapy. ( Barni, S; Galli, MA; Lissoni, P; Tancini, G, 1993) |
| "This study has been initiated to investigate whether sunitinib (SUN) alters the expression of key genes engaged in mitochondrial transport and oxidation of long chain fatty acids (LCFA), and if so, whether these alterations should be viewed as a mechanism of SUN-induced cardiotoxicity, and to explore the molecular mechanisms whereby carnitine supplementation could attenuate SUN-induced cardiotoxicity." | 3.91 | Carnitine Supplementation Attenuates Sunitinib-Induced Inhibition of AMP-Activated Protein Kinase Downstream Signals in Cardiac Tissues. ( Abdullah, ML; Al-Shabanah, OA; Alrikabi, A; Alrufaiq, BI; Hafez, MM; Sayed-Ahmed, MM, 2019) |
| "Perfluorooctanoic acid (PFOA), a wide spread environmental pollutant, was associated with developmental cardiotoxicity in chicken embryo, while the underlying molecular mechanism had not been fully elucidated." | 3.88 | The roles of bone morphogenetic protein 2 in perfluorooctanoic acid induced developmental cardiotoxicity and l-carnitine mediated protection. ( Cui, L; Han, Y; Jiang, Q; Lv, N; Wang, C; Zhao, M; Zhong, W, 2018) |
| " The aim of this study was to analyze which mechanisms are involved in the cardiotoxicity caused by Su, as well as to explore the potential cardioprotective effects of l-carnitine (LC)." | 3.83 | Inflammatory and fibrotic processes are involved in the cardiotoxic effect of sunitinib: Protective role of L-carnitine. ( Aramburu, O; Arévalo, M; Arias, JL; Blanca, AJ; Mate, A; Miguel-Carrasco, JL; Ruiz-Armenta, MV; Vázquez, CM; Zambrano, S, 2016) |
| "Carnitine is a conditionally necessary vitamin that aids in energy creation and fatty acid metabolism." | 3.01 | Biomedical role of L-carnitine in several organ systems, cellular tissues, and COVID-19. ( Al-Dhuayan, IS, 2023) |
| "Carnitine has a critical role in energy metabolism." | 2.36 | Carnitine. ( Borum, PR, 1983) |
| "Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disorder." | 1.56 | L-carnitine supplementation attenuates NAFLD progression and cardiac dysfunction in a mouse model fed with methionine and choline-deficient diet. ( Codella, R; Luzi, L; Mollica, G; Montesano, A; Senesi, P; Terruzzi, I; Vacante, F, 2020) |
| "Carnitine deficiency was induced in Wistar rats by adding 20 mmol/L of sodium pivalate to drinking water (P)." | 1.43 | A Moderate Carnitine Deficiency Exacerbates Isoproterenol-Induced Myocardial Injury in Rats. ( Arduini, A; Bonomini, M; Giudice, PL, 2016) |
| "In total, 32 patients with beta-thalassemia major were recruited; 16 age- and sex-matched children constituted the control group." | 1.35 | Pulmonary hypertension in beta-thalassemia major and the role of L-carnitine therapy. ( El Accaoui, R; El-Beshlawy, A; El-Saidi, S; Makhlouf, A; Mansi, Y; Taher, A; Youssry, I, 2008) |
| "Carnitine is an essential cofactor for fatty acid (FA) metabolism, the predominant source of ATP in the normal aerobic heart." | 1.32 | Plasma carnitine concentrations in patients undergoing open heart surgery. ( Miyoshi, Y; Nakamura, K; Nemoto, S; Sakai, A; Yasuhara, K, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (34.04) | 18.7374 |
| 1990's | 10 (21.28) | 18.2507 |
| 2000's | 9 (19.15) | 29.6817 |
| 2010's | 8 (17.02) | 24.3611 |
| 2020's | 4 (8.51) | 2.80 |
| Authors | Studies |
|---|---|
| Vaughan, OR | 1 |
| Rosario, FJ | 1 |
| Chan, J | 1 |
| Cox, LA | 1 |
| Ferchaud-Roucher, V | 1 |
| Zemski-Berry, KA | 1 |
| Reusch, JEB | 1 |
| Keller, AC | 1 |
| Powell, TL | 1 |
| Jansson, T | 1 |
| Al-Dhuayan, IS | 1 |
| Mollica, G | 1 |
| Senesi, P | 1 |
| Codella, R | 1 |
| Vacante, F | 1 |
| Montesano, A | 1 |
| Luzi, L | 1 |
| Terruzzi, I | 1 |
| Park, DD | 1 |
| Gahr, BM | 1 |
| Krause, J | 1 |
| Rottbauer, W | 1 |
| Zeller, T | 1 |
| Just, S | 1 |
| Mustafa, HN | 1 |
| Hegazy, GA | 1 |
| Awdan, SAE | 1 |
| AbdelBaset, M | 1 |
| Wang, ZY | 1 |
| Liu, YY | 1 |
| Liu, GH | 1 |
| Lu, HB | 1 |
| Mao, CY | 1 |
| Pan, YJ | 1 |
| Lu, FP | 1 |
| Lv, N | 1 |
| Zhao, M | 1 |
| Han, Y | 1 |
| Cui, L | 1 |
| Zhong, W | 1 |
| Wang, C | 1 |
| Jiang, Q | 1 |
| Sayed-Ahmed, MM | 1 |
| Alrufaiq, BI | 1 |
| Alrikabi, A | 1 |
| Abdullah, ML | 1 |
| Hafez, MM | 1 |
| Al-Shabanah, OA | 1 |
| Sizova, ZM | 1 |
| Shikh, EV | 1 |
| Makhova, AA | 1 |
| Blanca, AJ | 1 |
| Ruiz-Armenta, MV | 1 |
| Zambrano, S | 1 |
| Miguel-Carrasco, JL | 1 |
| Arias, JL | 1 |
| Arévalo, M | 1 |
| Mate, A | 1 |
| Aramburu, O | 1 |
| Vázquez, CM | 1 |
| Giudice, PL | 1 |
| Bonomini, M | 2 |
| Arduini, A | 2 |
| El-Beshlawy, A | 2 |
| Youssry, I | 1 |
| El-Saidi, S | 1 |
| El Accaoui, R | 1 |
| Mansi, Y | 1 |
| Makhlouf, A | 2 |
| Taher, A | 2 |
| Turer, AT | 1 |
| Stevens, RD | 1 |
| Bain, JR | 1 |
| Muehlbauer, MJ | 1 |
| van der Westhuizen, J | 1 |
| Mathew, JP | 1 |
| Schwinn, DA | 1 |
| Glower, DD | 1 |
| Newgard, CB | 1 |
| Podgoreanu, MV | 1 |
| Zammit, VA | 1 |
| Ramsay, RR | 1 |
| Yaris, N | 1 |
| Ceviz, N | 1 |
| Coskun, T | 1 |
| Akytüz, C | 1 |
| Büyükpamukçu, M | 1 |
| Nemoto, S | 1 |
| Yasuhara, K | 1 |
| Nakamura, K | 1 |
| Miyoshi, Y | 1 |
| Sakai, A | 1 |
| Pion, PD | 2 |
| Ragab, L | 1 |
| Fattah, AA | 1 |
| Ibrahim, IY | 1 |
| Hamdy, M | 1 |
| Aoun, E | 1 |
| Hoffbrand, V | 1 |
| Borum, PR | 1 |
| Bamji, MS | 1 |
| Maccari, F | 1 |
| Ramacci, MT | 1 |
| Watanabe, S | 1 |
| Ajisaka, R | 1 |
| Masuoka, T | 1 |
| Yamanouchi, T | 1 |
| Saitou, T | 1 |
| Toyama, M | 1 |
| Takeyasu, N | 1 |
| Sakamoto, K | 1 |
| Sugishita, Y | 1 |
| Smith, CA | 1 |
| Matsui, S | 1 |
| Sugita, T | 1 |
| Matoba, M | 1 |
| Murakami, E | 1 |
| Takekoshi, N | 1 |
| Shinka, T | 1 |
| Matsumoto, I | 1 |
| Lissoni, P | 1 |
| Galli, MA | 1 |
| Tancini, G | 1 |
| Barni, S | 1 |
| Weber, R | 1 |
| Boyle, C | 1 |
| Klein, HO | 1 |
| Sanderson, SL | 1 |
| Kittelson, MD | 1 |
| Löster, H | 1 |
| Miehe, K | 1 |
| Punzel, M | 1 |
| Stiller, O | 1 |
| Pankau, H | 1 |
| Schauer, J | 1 |
| Nakamura, T | 1 |
| Sugihara, H | 1 |
| Kinoshita, N | 1 |
| Yoneyama, S | 1 |
| Azuma, A | 1 |
| Nakagawa, M | 1 |
| Bratton, SL | 1 |
| Garden, AL | 1 |
| Bohan, TP | 1 |
| French, JW | 1 |
| Clarke, WR | 1 |
| Dhalla, NS | 1 |
| Elimban, V | 1 |
| Rupp, H | 1 |
| el Alaoui-Talibi, Z | 2 |
| Moravec, J | 2 |
| Hamlin, RL | 1 |
| Buffington, CA | 1 |
| Tahiliani, AG | 2 |
| McNeill, JH | 2 |
| Mortensen, SA | 1 |
| Aabo, K | 1 |
| Jonsson, T | 1 |
| Baandrup, U | 1 |
| De Leonardis, V | 2 |
| De Scalzi, M | 1 |
| Neri, B | 2 |
| Bartalucci, S | 1 |
| Cinelli, P | 2 |
| Cugurra, F | 1 |
| DiPalma, JR | 1 |
| Bacalli, S | 1 |
| Shipp, JC | 1 |
| Menahan, LA | 1 |
| Crass, MF | 1 |
| Chaudhuri, SN | 1 |
| Munro, IC | 1 |
| Salem, FA | 1 |
| Goodman, T | 1 |
| Hasnain, SH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of Acetyl L-Carnitine in Patients With Covid-19 Pneumonia[NCT04623619] | 100 participants (Anticipated) | Interventional | 2020-12-15 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for carnitine and Cardiac Diseases
| Article | Year |
|---|---|
Biomedical role of L-carnitine in several organ systems, cellular tissues, and COVID-19.
Topics: Carnitine; COVID-19; Dietary Supplements; Heart Diseases; Humans; Liver Cirrhosis | 2023 |
l-Carnitine and heart disease.
Topics: Animals; Arrhythmias, Cardiac; Cardiotonic Agents; Carnitine; Heart; Heart Diseases; Humans; Myocard | 2018 |
Significance of L-carnitine in internal medicine.
Topics: Antioxidants; Carnitine; Cytochrome P-450 CYP3A; Heart; Heart Diseases; Heart Failure; Humans; Inter | 2019 |
Carnitine, mitochondrial function and therapy.
Topics: Animals; Carnitine; Carnitine Acyltransferases; Heart Diseases; Humans; Mitochondria | 2009 |
Traditional and nontraditional effective and noneffective therapies for cardiac disease in dogs and cats.
Topics: Animals; Cardiotonic Agents; Carnitine; Cat Diseases; Cats; Complementary Therapies; Dog Diseases; D | 2004 |
Carnitine.
Topics: Animals; Biological Transport; Carnitine; Energy Metabolism; Heart Diseases; Humans; Kidney Diseases | 1983 |
Cardiac carnitine-binding protein.
Topics: Animals; Carnitine; Carrier Proteins; Cricetinae; Heart Diseases; Metabolism, Inborn Errors; Myocard | 1984 |
Nutritional and health implications of lysine carnitine relationship.
Topics: Animals; Carnitine; Glycine Hydroxymethyltransferase; Heart Diseases; Humans; Kidney Diseases; Liver | 1984 |
The effectiveness of taurine and levocarnitine in dogs with heart disease.
Topics: Animals; Cardiotonic Agents; Carnitine; Dog Diseases; Dogs; Heart Diseases; Taurine | 1998 |
Paradoxical role of lipid metabolism in heart function and dysfunction.
Topics: Adenosine Triphosphatases; Animals; Carnitine; Diabetes Complications; Diabetes Mellitus; Diabetes M | 1992 |
Nutrition and the heart.
Topics: Animals; Cachexia; Carnitine; Cat Diseases; Cats; Diet; Dog Diseases; Dogs; Heart Diseases; Heart Fa | 1989 |
Diabetes-induced abnormalities in the myocardium.
Topics: Adenosine Triphosphatases; Animals; Blood Glucose; Calcium; Carbohydrate Metabolism; Cardiomyopathie | 1986 |
[Drug therapy possibilities for the senile heart].
Topics: Aged; Aging; Anti-Arrhythmia Agents; Antihypertensive Agents; Calcium Channel Blockers; Cardiotonic | 1986 |
Heart triglycerides in health and disease.
Topics: Animals; Carnitine; Coenzyme A; Coronary Disease; Diabetes Mellitus; Fatty Acids, Nonesterified; Gly | 1973 |
4 trials available for carnitine and Cardiac Diseases
| Article | Year |
|---|---|
Improvement of cardiac function in thalassemia major treated with L-carnitine.
Topics: Adolescent; Adult; Angiography; beta-Thalassemia; Carnitine; Child; Electrocardiography; Female; Hea | 2004 |
Effects of L- and DL-carnitine on patients with impaired exercise tolerance.
Topics: Administration, Oral; Aged; Cardiac Output; Carnitine; Exercise Test; Exercise Tolerance; Female; He | 1995 |
Prevention by L-carnitine of interleukin-2 related cardiac toxicity during cancer immunotherapy.
Topics: Adult; Aged; Cardiomyopathies; Carnitine; Drug Therapy, Combination; Female; Heart Diseases; Humans; | 1993 |
Prolonged oral L-carnitine substitution increases bicycle ergometer performance in patients with severe, ischemically induced cardiac insufficiency.
Topics: Adult; Aged; Blood Pressure; Carnitine; Double-Blind Method; Energy Metabolism; Exercise; Female; He | 1999 |
29 other studies available for carnitine and Cardiac Diseases
| Article | Year |
|---|---|
Maternal obesity causes fetal cardiac hypertrophy and alters adult offspring myocardial metabolism in mice.
Topics: Adult Children; Animals; Cardiomegaly; Cardiovascular Diseases; Carnitine; Female; Fetal Heart; Hear | 2022 |
L-carnitine supplementation attenuates NAFLD progression and cardiac dysfunction in a mouse model fed with methionine and choline-deficient diet.
Topics: Animals; Carnitine; Choline Deficiency; Diet; Dietary Supplements; Disease Models, Animal; Disease P | 2020 |
Long-Chain Acyl-Carnitines Interfere with Mitochondrial ATP Production Leading to Cardiac Dysfunction in Zebrafish.
Topics: Adenosine Triphosphate; Animals; Carnitine; Disease Models, Animal; Fatty Acids; Heart; Heart Diseas | 2021 |
Protective role of CoQ10 or L-carnitine on the integrity of the myocardium in doxorubicin induced toxicity.
Topics: Animals; Cardiotoxicity; Carnitine; Doxorubicin; Female; Heart Diseases; Myocardium; Oxidative Stres | 2017 |
[Supplementation with high-dose L-carnitine on hemodialysis tolerance in uremic patients with severe heart diseases].
Topics: Carnitine; Heart Diseases; Humans; Immune Tolerance; Kidney Failure, Chronic; Renal Dialysis | 2017 |
The roles of bone morphogenetic protein 2 in perfluorooctanoic acid induced developmental cardiotoxicity and l-carnitine mediated protection.
Topics: Animals; Bone Morphogenetic Protein 2; Caprylates; Cardiotoxicity; Carnitine; Chick Embryo; Cytoprot | 2018 |
Carnitine Supplementation Attenuates Sunitinib-Induced Inhibition of AMP-Activated Protein Kinase Downstream Signals in Cardiac Tissues.
Topics: Acetyl-CoA Carboxylase; Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Antineoplast | 2019 |
Inflammatory and fibrotic processes are involved in the cardiotoxic effect of sunitinib: Protective role of L-carnitine.
Topics: Animals; Antineoplastic Agents; Blood Pressure; Cardiotonic Agents; Cardiotoxicity; Carnitine; Cytok | 2016 |
A Moderate Carnitine Deficiency Exacerbates Isoproterenol-Induced Myocardial Injury in Rats.
Topics: Animals; Cardiomyopathies; Carnitine; Diastole; Heart; Heart Diseases; Heart Rate; Hyperammonemia; I | 2016 |
Pulmonary hypertension in beta-thalassemia major and the role of L-carnitine therapy.
Topics: Administration, Oral; Adolescent; beta-Thalassemia; Carnitine; Case-Control Studies; Child; Child, P | 2008 |
Metabolomic profiling reveals distinct patterns of myocardial substrate use in humans with coronary artery disease or left ventricular dysfunction during surgical ischemia/reperfusion.
Topics: Aged; Anaerobic Threshold; Cardiac Output; Cardiopulmonary Bypass; Carnitine; Coronary Artery Diseas | 2009 |
Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity.
Topics: Adolescent; Antibiotics, Antineoplastic; Carnitine; Case-Control Studies; Child; Child, Preschool; D | 2002 |
Plasma carnitine concentrations in patients undergoing open heart surgery.
Topics: Adult; Aged; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Carnitine; Female; Heart Diseases; | 2004 |
Carnitine promising, but no miracle for heart disease. Hype for the dietary supplement carnitine as a treatment for heart disease far outstrips the evidence.
Topics: Carnitine; Heart Diseases; Humans; Myocardium | 2005 |
Antagonism of doxorubicin cardiotoxicity by carnitine is specific of the L-diasteroisomer.
Topics: Animals; Carnitine; Coronary Circulation; Doxorubicin; Heart Diseases; Heart Rate; Male; Myocardial | 1981 |
Looking for consensus in treatment of cardiac disease.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Bronchodilator Agents; Cardiotonic Age | 1995 |
Urinary carnitine excretion in patients with heart failure.
Topics: Acetylcarnitine; Aged; Cardiac Output, Low; Carnitine; Female; Heart Diseases; Humans; Male; Middle | 1994 |
[What physicians ought to know about L-carnitine: basic considerations].
Topics: Adult; Carnitine; Heart Diseases; Humans; Infant; Metabolism, Inborn Errors | 1993 |
Anthracycline-induced cardiotoxicity.
Topics: Anthracyclines; Antineoplastic Agents; Carnitine; Heart Diseases; Humans | 1997 |
Can serum carnitine levels distinguish hypertrophic cardiomyopathy from hypertensive hearts?
Topics: Adult; Aged; Analysis of Variance; Cardiomyopathy, Hypertrophic; Carnitine; Diagnosis, Differential; | 2000 |
A child with valproic acid-associated carnitine deficiency and carnitine-responsive cardiac dysfunction.
Topics: Carnitine; Child; Developmental Disabilities; Heart Diseases; Humans; Male; Metabolic Diseases; Myoc | 1992 |
Carnitine transport and exogenous palmitate oxidation in chronically volume-overloaded rat hearts.
Topics: Animals; Biological Transport; Carbon Dioxide; Carnitine; Heart Diseases; In Vitro Techniques; Myoca | 1989 |
Clinical and non-invasive assessment of anthracycline cardiotoxicity: perspectives on myocardial protection.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 1986 |
Echocardiographic assessment of anthracycline cardiotoxicity during different therapeutic regimens.
Topics: Adult; Breast Neoplasms; Carnitine; Doxorubicin; Echocardiography; Epirubicin; Female; Heart Disease | 1987 |
Decreased L-carnitine transport in mechanically overloaded rat hearts.
Topics: Animals; Biological Transport; Carnitine; Female; Heart Diseases; Kinetics; Myocardium; Rats; Rats, | 1987 |
Effects of triiodothyronine and carnitine therapy on myocardial dysfunction in diabetic rats.
Topics: Animals; Carnitine; Diabetes Mellitus, Experimental; Female; Heart Diseases; Myocardial Contraction; | 1986 |
L-carnitine: its therapeutic potential.
Topics: Carnitine; Chemical Phenomena; Chemistry; Diagnosis, Differential; Heart Diseases; Humans; Kidney Di | 1986 |
Reduction of cardiac toxicity of anthracyclines by L-carnitine: preliminary overview of clinical data.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Carnitine; Creatine Kinase; Doxorubicin; Echoc | 1985 |
Biochemical and pathological changes in the heart and liver of rats given brominated cottonseed oil.
Topics: Adenosine Triphosphate; Animals; Bromine; Carbon Isotopes; Carnitine; Chemical and Drug Induced Live | 1971 |